We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.97%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$522M
AUM Growth
-$108M
Cap. Flow
-$65.4M
Cap. Flow %
-12.54%
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.3M
2
MDT icon
Medtronic
MDT
+$16.9M
3
PFE icon
Pfizer
PFE
+$10.7M
4
ELV icon
Elevance Health
ELV
+$7.8M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$6.07M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$26.6M
2
CELG
Celgene Corp
CELG
+$10.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$8.57M
4
UNH icon
UnitedHealth
UNH
+$8.21M
5
MRK icon
Merck
MRK
+$7.97M

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Financials 1.61%
3 Technology 0.16%
4 Energy 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$162B
$18.6M 3.57%
+259,894
New +$19.3M
BMY icon
2
Bristol-Myers Squibb
BMY
$133B
$16.4M 3.15%
281,000
+44,000
+19% +$2.41M
AGN
3
DELISTED
Allergan plc
AGN
$16M 3.06%
76,000
-3,500
-4% -$725K
LLY icon
4
Eli Lilly
LLY
$1.02T
$15.8M 3.03%
215,000
-40,000
-16% -$2.98M
MDT icon
5
Medtronic
MDT
$109B
$15.3M 2.94%
+215,240
New +$16.9M
INCY icon
6
Incyte
INCY
$24.2B
$14M 2.69%
140,000
-45,000
-24% -$4.39M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$40.8B
$13.1M 2.5%
360,000
+90,000
+33% +$3.59M
EXEL icon
8
Exelixis
EXEL
$13.3B
$12.4M 2.37%
830,000
+230,000
+38% +$3.32M
UNH icon
9
UnitedHealth
UNH
$376B
$12M 2.3%
75,017
-54,983
-42% -$8.21M
ABMD
10
DELISTED
Abiomed Inc
ABMD
$11.6M 2.22%
102,700
+17,700
+21% +$2.05M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.3M 2.17%
700,000
+335,000
+92% +$6.07M
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$11.2M 2.15%
91,702
-70,000
-43% -$8.57M
ARIA
13
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$11.1M 2.13%
895,000
+220,000
+33% +$2.65M
CVS icon
14
CVS Health
CVS
$133B
$11M 2.12%
140,000
-20,000
-13% -$1.62M
PFE icon
15
Pfizer
PFE
$143B
$10.8M 2.08%
+351,298
New +$10.7M
CELG
16
DELISTED
Celgene Corp
CELG
$10.8M 2.06%
93,000
-93,000
-50% -$10.4M
BIIB icon
17
Biogen
BIIB
$30B
$10.2M 1.96%
36,000
-21,000
-37% -$6.22M
REGN icon
18
Regeneron Pharmaceuticals
REGN
$78.5B
$9.73M 1.86%
26,500
-3,000
-10% -$1.14M
AMGN icon
19
Amgen
AMGN
$208B
$9.5M 1.82%
65,000
+10,000
+18% +$1.51M
CI icon
20
Cigna
CI
$73.7B
$9.2M 1.76%
69,000
-15,000
-18% -$1.96M
CNC icon
21
Centene
CNC
$30.7B
$8.48M 1.63%
300,000
+140,000
+88% +$4.13M
ELV icon
22
Elevance Health
ELV
$81.5B
$8.38M 1.61%
+58,257
New +$7.8M
ZBH icon
23
Zimmer Biomet
ZBH
$18.2B
$8.26M 1.58%
82,400
-5,150
-6% -$552K
HUM icon
24
Humana
HUM
$43.7B
$8.16M 1.56%
40,000
+15,000
+60% +$2.86M
HCA icon
25
HCA Healthcare
HCA
$87.2B
$7.75M 1.49%
104,707
-5,293
-5% -$396K
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rhenman & Partners Asset Management held 119 positions worth $522M, down 17% from $630M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $65.4M in Q4 2016, closing 11 positions and reducing 37 holdings. Its most notable exit was Shire pic, an estimated $26.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 86% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Gilead Sciences worth $18.6M.

  • Rhenman & Partners Asset Management's largest Q4 2016 buy was Gilead Sciences: 259,894 shares worth $18.6M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016, an estimated $6.07M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2016 reduction was Celgene Corp, cutting an estimated $10.4M.
  • Rhenman & Partners Asset Management fully exited Shire pic in Q4 2016, selling an estimated $26.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $522M portfolio in Q4 2016.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 11 in Q4 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 17% quarter-over-quarter to $522M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2016, filed 13 Jan 2017.